Hepatitis B Clinical Trials

• Healthy Participants:

• Male or female participants, aged 18-55 years old (inclusive);

• Body mass index between 18.0 and 28.0 kg/m\^2 (inclusive);

• Laboratory safety tests during the screening period, 12-lead electrocardiogram (ECG), abdominal ultrasound, thyroid ultrasound, chest anteroposterior position, etc., are assessed by the investigatoras normal or abnormal without clinical significance;

• Female participants of childbearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening, and must agree to use effective contraceptive methods and refrain from donating eggs from screening until 6 months after the last dose of the study drug.

• Male participants must agree to use highly effective contraceptive methods (to ensure effective contraception for their female partners of childbearing potential) and refrain from donating sperm from screening until 6 months after the last dose of the study drug. Liver and kidney function tests meet the requirements at the time of screening.

• CHB Participants:

• Male or female participants, aged 18-65 years old (inclusive);

• Body mass index between 18.0 and 32.0 kg/m\^2 (inclusive);

• Participants who take effective contraceptive measures as required;

• HBsAg \> 100 IU/mL and ≤ 3000 IU/mL, and HBV DNA \< 100 IU/mL at screening.

• Have received stable treatment with NA for at least 6 months and stable on the same NA for at least 3 months before screening.